Daily Archives: 8th November 2018
Daily Archives: 8th November 2018
|🇩🇪 10 Yr Bund
|iBoxx Corp IG
|iBoxx Corp HY
|🇺🇸 10 Yr US T-Bond
|🇬🇧 FTSE 100 [wp_live_scraper id=”17″], [wp_live_scraper id=”24″]||🇩🇪 DAX [wp_live_scraper id=”19″], [wp_live_scraper id=”25″]||🇺🇸 S&P 500 [wp_live_scraper id=”21″], [wp_live_scraper id=”26″]|
The recovery lasted all but a day. Nevertheless, primary has reopened, the deal flow looks a lot better and could potentially be sustainable – even if equities only tread water for a while. US pharmaceutical group Allergan along with BMW and Intercontinental Hotels piped up for the IG non-financial market in the week’s penultimate session, adding another €4bn to the issuance level.
Away from that, the jousting continues between the European Commission and Italy while Eurozone macro is feeling the chill as evidenced by the weak trade data for Germany in September (exports and imports down by 0.8% and 0.4%, respectively).
We had Societe Generale (SOCGEN) and Unicredito (UCGIM) report Q3 earnings on Thursday and whilst the underlying core earnings story was more or less the same, equity investors were more upbeat on SOCGEN’s earnings (stock was up 3%) and less so on UCGIM (down 4%). This just reiterates the fact that investors place a much higher risk premium on Italian banks, given the sovereign linkage.
In many ways, both banks have a similar business model – well-entrenched domestic retail franchise, specialised financial services, central and eastern European presence and an investment banking focusing on niche areas.
UCGIM’s earnings were impacted by the write-downs to its stake in Yapi (its Turkey subsidiary) but underlying earnings were decent with reported adjusted ROTE of 8.3%. With credit costs under control and ongoing internal business restructuring, reported earnings were better than feared. The significant restructuring of the bank, especially in its non-core unit, is clearly having an impact on its turnaround prospects.
SOCGEN’s earnings were clearly boosted by the better performance in the investment bank especially in equities and that meant the bank reported a decent 11% on ROTE. The sustainability of the investment bank performance is yet to be established. The question is – should investors be happy with the 11% ROTE – given the bank’s presence in Russia and its specialised consumer finance business and its large equity derivatives business.
Asset quality is the one area where UCGIM still suffers from investor pessimism. With its large non-performing exposure (NPE) of 8.3%, it is still a long way to go relative to its large cap European bank peers. The creation of the non-core unit to handle legacy NPE has helped in bringing down the numbers from double digits in previous years. SOCGEN’s non-performing loans are around 3.8% reflecting its loan book underwriting and credit risk management.
On capital metrics, it remains to be seen if the sharp drop in UCGIM’s CET 1 ratio (almost 40 bps this quarter) to 12.1% and a similar drop in leverage ratio to 5% is a one-off. Though the CET1 ratio and leverage ratio is much higher than many of its European peers, it is still not high enough to weather an all-out risk-off scenario either due to Italian politics and/or EM crisis
SOCGEN reported a CET1 ratio of 11.2% and leverage ratio of 4.1% which is decent and in line with French peers but in my opinion not strong enough to weather multiple headwinds. It seems that the French banks can get away with the lower CET1 and leverage ratios given their domicile and perceived fundamental strength.
UCGIM stock was down 4% today whilst SOCGEN stock was up nearly 3%. Funnily enough, both banks have experienced sharp falls in their stock prices over the year and have almost similar market capitalisation (UCGIM market cap is around EUR 25 billion and SOCGEN is around EUR 27.5 billion). UCGIM stock is down 30% YTD and is trading at a Price /TNAV of 0.5 times whereas SOCGEN stock is down about 22% YTD and is trading at a Price/TNAV of 0.6 times. To that extent, not much to choose from but one must guess that is the reason for the constant noise that a merger between the two may make sense.
It depends on the risk premium that investors want to attach to the very similar (but slightly different) business models. UCGIM will continue to need a much higher risk premium given its Italian base and presence in Turkey and large level of NPEs. SOCGEN, which although at first glance seems less risky, probably needs a higher risk premium as well given its Russia and Equity derivatives franchise.
As far as credit investors are concerned, AT1s issued by SOCGEN are much better to own given the 7%+ yields relative to the bank’s LT2s and non-preferred senior paper.
And in the case of UCGIM think LT2s better to own ahead of its AT1s. UCGIM’s AT1 yields (8%+ in some issues) are attractive no doubt but overall the cash price is still too high for the tail risks out there, and in the event of market anticipating a trigger, the price drop would be substantial.